Enliven Therapeutics, Inc. (ELVN)

NASDAQ: ELVN · IEX Real-Time Price · USD
24.74
+0.68 (2.83%)
Jul 12, 2024, 4:00 PM EDT - Market closed
2.83%
Market Cap 1.16B
Revenue (ttm) n/a
Net Income (ttm) -79.60M
Shares Out 47.04M
EPS (ttm) -1.92
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 568,935
Open 24.64
Previous Close 24.06
Day's Range 23.67 - 25.34
52-Week Range 9.80 - 26.00
Beta n/a
Analysts Strong Buy
Price Target 33.00 (+33.39%)
Earnings Date Aug 8, 2024

About ELVN

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado. [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Mar 12, 2020
Employees 50
Stock Exchange NASDAQ
Ticker Symbol ELVN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for ELVN stock is "Strong Buy." The 12-month stock price forecast is $33.0, which is an increase of 33.39% from the latest price.

Price Target
$33.0
(33.39% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Enliven Therapeutics to Present at Two Upcoming Investor Conferences

BOULDER, Colo., May 29, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven) (Nasdaq: ELVN), a clinical-stage precision oncology company focused on the discovery and development of next-gener...

6 weeks ago - GlobeNewsWire

Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update

Announced positive proof of concept data from Phase 1 clinical trial of ELVN-001 in CML, achieving an initial cumulative MMR rate of 44% (7/16) by 12 weeks in response-evaluable patients

2 months ago - GlobeNewsWire

Enliven Therapeutics Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia

Achieved initial cumulative MMR rate of 44% (7/16) by 12 weeks in response-evaluable patients, which compares favorably to precedent Phase 1 trials of approved BCR::ABL1 TKIs

3 months ago - GlobeNewsWire

Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directors

BOULDER, Colo., April 09, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage precision oncology company focused on the discovery and developm...

3 months ago - GlobeNewsWire

Enliven Therapeutics to Share Initial Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 and Host Virtual Key Opinion Leader Event on April 11, 2024

BOULDER, Colo., March 28, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage precision oncology company focused on the discovery and developm...

3 months ago - GlobeNewsWire

Enliven Therapeutics Announces $90 Million Private Placement Financing and Provides Pipeline Updates

Financing includes participation from new and existing investors Net proceeds, along with existing cash, cash equivalents and marketable securities, are expected to extend cash runway into late 2026 a...

4 months ago - GlobeNewsWire

Enliven Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update

Initial proof of concept data from Phase 1a trial evaluating ELVN-001 in adults with chronic myeloid leukemia (CML) is expected in the second quarter of 2024

4 months ago - GlobeNewsWire

Enliven Therapeutics to Present at TD Cowen's 44th Annual Health Care Conference

BOULDER, Colo., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven) (Nasdaq: ELVN), a clinical-stage precision oncology focused on the discovery and development of next-generation s...

4 months ago - GlobeNewsWire

Enliven Therapeutics Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress

Continued progress of parallel lead programs, ELVN-001 and ELVN-002, through dose escalation in Phase 1 trials, with initial proof of concept data for both programs expected in 2024

1 year ago - GlobeNewsWire

Enliven Therapeutics Closes Merger with Imara and Private Placement of $165 Million

Combined company will be focused on advancing Enliven's clinical-stage pipeline of precision oncology programs

1 year ago - GlobeNewsWire

Imara Announces Stockholder Approval of Merger With Enliven

-- Combined Company to Trade on Nasdaq Under Ticker “ELVN” -- -- Imara Announces 1-for-4 Reverse Stock Split of Common Stock -- BROOKLINE, Mass., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: ...

1 year ago - GlobeNewsWire

IMARA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Imara Inc. - IMRA

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Imara Inc. (...

1 year ago - Business Wire

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates FCRD, KNBE, IMRA

NEW YORK , Dec. 6, 2022 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches ...

1 year ago - PRNewsWire

SHAREHOLDER ALERT: Weiss Law Investigates IMARA Inc.

NEW YORK , Oct. 14, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of IMARA Inc. ("IMARA" or the "Company") (...

1 year ago - PRNewsWire

IMRA Stock Alert: Halper Sadeh LLC is Investigating Whether the Merger of Imara Inc. is Fair to Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Imara Inc. (NASDAQ: IMRA) and Enliven Therapeutics, Inc. is fair to Imara shareholders.

1 year ago - Business Wire

Enliven Therapeutics and Imara Announce Merger Agreement

Boulder, CO and Boston, MA, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven), a clinical-stage precision oncology company focused on the discovery and development of next-generat...

1 year ago - GlobeNewsWire

Read Why Imara Shares Are Falling Today

Imara Inc (NASDAQ: IMRA) shares are falling after interim analyses of its Ardent Phase 2b trial of tovinontrine (IMR-687) in sickle cell disease (SCD) and Forte Phase 2b trial in beta-thalassemia.  Da...

2 years ago - Benzinga

Imara Announces Results of Interim Analyses of Tovinontrine (IMR-687) Phase 2b Clinical Trials in Sickle Cell Disease and Beta-Thalassemia

Interim results in Ardent trial for sickle cell disease showed no significant difference in median annualized rate of vaso-occlusive crises in high-dose group versus placebo in an intent-to-treat popu...

2 years ago - GlobeNewsWire

Imara Reports Full Year 2021 Financial Results and Business Highlights

Completed enrollment in Phase 2b sickle cell disease and beta-thalassemia trials with tovinontrine (IMR-687); expect to report both interim datasets in first week of April 2022

2 years ago - GlobeNewsWire

Imara to Webcast Conference Call of Full Year 2021 Financial Results and Business Highlights

BOSTON, March 08, 2022 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffer...

2 years ago - GlobeNewsWire

Imara to Present at 11th Annual SVB Leerink Global Healthcare Conference

BOSTON, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients sufferi...

2 years ago - GlobeNewsWire

Imara To Start Testing Tovinontrine In Heart Failure Patients

The FDA signed off Imara Inc's (NASDAQ: IMRA) investigational new drug (IND) application for tovinontrine (IMR-687) in heart failure with preserved ejection fraction (HFpEF). The Company plans to init...

2 years ago - Benzinga

Imara Announces FDA Clearance of Investigational New Drug Application (IND) for Tovinontrine (IMR-687) for Heart Failure with Preserved Ejection Fraction (HFpEF)

Expanding patient base and potential of Imara's small molecule oral inhibitor of phosphodiesterase-9 (PDE9) alongside hemoglobin disorders

2 years ago - GlobeNewsWire

Imara to Present at the H.C. Wainwright BioConnect 2022 Virtual Conference

BOSTON, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat subjects sufferi...

2 years ago - GlobeNewsWire

Imara Presents Preclinical Data on IMR-261 at the American Society of Hematology (ASH) Annual Meeting 2021

Oral presentation provides first look at new program, IMR-261, a novel, oral, clinic-ready nuclear factor erythroid 2-related factor 2 (Nrf2) activator

2 years ago - GlobeNewsWire